In a significant move to bolster its pharmaceutical manufacturing capabilities, Evonik is pouring $100 million into upgrading its drug substance production site in Lafayette, Indiana. This substantial investment aims to meet the surging demand for U.S.-based contract development and manufacturing organizations (CDMOs) and enhance the company’s ability to handle increasingly complex active pharmaceutical ingredients (APIs).
The investment is part of Evonik’s broader strategy to balance its global asset footprint and invest in Next Generation Technologies. The modernization efforts will focus on upgrading key equipment, including 100 m³ reactors and other critical systems, to improve reliability, automation, ergonomics, and efficiency.
Strengthening U.S. Manufacturing Capabilities
Evonik’s Lafayette site, also known as Tippecanoe Labs, is a cornerstone of the company’s global CDMO network for small-molecule drug substances. The site, acquired from Eli Lilly in 2010, has evolved into one of the world’s largest API facilities. It houses the industry’s biggest high-potency API (HPAPI) operation with 170 m³ of dedicated capacity and advanced containment systems.
The investment is supported by local government and is expected to secure jobs and contribute to the local economy. The modernization efforts will help Evonik maintain its technology leadership and enhance energy-efficient processes, aligning with the company’s strict CAPEX guiding principles.
Meeting the Demand for Complex APIs
Geopolitical uncertainties and the increasing complexity of modern therapeutic goals have underscored the importance of regional production for critical drug substances. Evonik’s investment will enable the company to work with customers on even more challenging molecules for critical indications such as cancer, metabolic, and cardiovascular diseases.
The Tippecanoe site offers 860 m³ of reactor capacity for general APIs, 2,500 m³ for large-scale fermentation, and a technology portfolio spanning 10 advanced platforms. This investment will further improve the site’s capabilities to handle the rising molecular complexity of APIs.
Evonik’s Commitment to Innovation
Evonik, a global chemical company headquartered in Essen, Germany, is known for its innovative strength and leading technological expertise. The company generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2026. With approximately 31,000 employees worldwide, Evonik is committed to providing customers with tailor-made products and solutions that offer a decisive competitive advantage.
The Custom Solutions segment, which includes the drug substance business, focuses on innovation-driven, tailor-made solutions for customers in specific growth markets. In 2026, the segment generated sales of €5.4 billion with around 9,500 employees.
This investment in the Lafayette site is a testament to Evonik’s commitment to strengthening its U.S. drug substance business and creating a more resilient and globally balanced asset footprint.
